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The use of HIV-1 env/SIVmac chimeric viruses expressing divergent HIV-1 envelopes of clinical isolates, facilitates homolo-
gous and heterologous evaluation of various recombinant HIV-1 envelope vaccine candidates in lower primates. In this
study we compare the in vitro and in vivo infectivity, via intravenous (IV) and intravaginal (IVAG) routes of infection, of stocks
of chimeric viruses expressing env from four different clade B HIV-1 isolates. The TCID50/ml was 7.1 1 104, 1.0 1 104, 6.3
1 104, and 1.2 1 103 for SHIVsf13 , SHIVHan2 , SHIVNM-3rn , and SHIVW6.1D , respectively, with a MID50/ml upon IV inoculation of
3.21 103, 3.21 104, 3.21 104, and 3.21 103, respectively. The same SHIVsf13 stock was infectious after IVAG administration,
requiring a 300-fold higher virus dose. Plasma antigenemia and cell-associated viremia were generally highest at weeks 2
or 4 after infection and decreased to subdetectable levels after 8–12 weeks. All infected animals tested developed anti-
HIV-1 gp120 antibodies. Inoculated virus dose showed no (linear) quantitative correlation with cellular virus load, duration
of viremia, plasma antigenemia, and anti-gp120 antibody titers. No significant changes in peripheral blood CD4 cell levels
were observed and none of the animals has shown evidence of disease progression to date (i.e., 13 months postinfection).
Four in vivo passages of cell-associated SHIVW6.1D did not result in increased virulence. Vaccine development studies in
macaques monkeys have become feasible with the use of various clade B HIV-1 env SHIV chimeras. q 1997 Academic Press
INTRODUCTION fection and reduction of virus load as endpoints upon
inoculation with chimeric viruses containing homologous
HIV-1 vaccine efficacy studies in lower primates have
and/or heterologous HIV-1 env genes (Stott et al., 1994;
largely relied on the use of simian immunodeficiency
Bogers et al., 1995; Lu et al., 1996b). The recently de-
virus (SIV) in macaques as a surrogate model for HIV-1
scribed pathogenic SHIV viruses (Joag et al., 1996; Reim-
infection. However, HIV-1 differs considerably from HIV-
ann et al., 1996a), may also be useful to screen the effi-
2 and SIV in terms of envelope, neutralization, and CTL
cacy of vaccines in protection from disease progression.
epitopes shown to play a role in protective immunity. The
Here we describe the in vitro and in vivo characteristics
recent construction of chimeric simian/human immuno-
of four different clade B HIV-1 SHIVs, expressing the env
deficiency viruses (SHIV) represents a significant ad-
of human HIV-1sf13 (Cheng-Mayer et al., 1991), HIV-1Han2vance in models for the preclinical development and
(Sauermann et al., 1990), HIV-1NL432 (Adachi et al., 1986),evaluation of candidate AIDS-vaccines. These chimeras
and HIV-1W6.1D (Groenink et al., 1991). Furthermore weutilize the SIVmac genetic background in which the env investigated whether one of the SHIVs was able to infect
(Shibata et al., 1990; Li et al., 1992; Luciw et al., 1995;
macaques via the mucosa, and finally one SHIV was
Lu et al., 1996a) or reverse transcriptase (RT) genes (U¨b-
passaged in vivo in an attempt to increase virulence.
erla et al., 1995) of SIV have been replaced by those of
HIV-1. It has been demonstrated by various groups that
MATERIALS AND METHODScynomolgus monkeys (Macaca fascicularis), pig-tailed
monkeys (Macaca nemestrina), and rhesus monkeys
Chimeric simian/human immunodeficiency (SHIV)(Macaca mulatta) can be infected with these chimeric
virusesviruses. The availability of HIV-1 envelope chimeric vi-
ruses may permit the evaluation of HIV-1 envelope-based The chimeric viruses SHIVsf13 and SHIVHan2 were gen-
vaccines in lower primates using protection against in- erated using SIVmac239 as the background virus (including
gag, pol, vif, vpx, and nef) as described (Kuwata et al.,
1996). The SHIVsf13 was constructed using env, vpu, vpr,1 To whom correspondence and reprint requests should be ad-
dressed. Fax. /31 152843986. E-mail: bogers@bprc.nl. rev, and tat from HIV-1sf13 . SHIVHan2 contains env and vpu
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from HIV-1Han2 , tat and vpr from HIV-1NL432 (Kuwata et al., The SHIVNM-3rn virus was prepared essentially as de-
scribed above for SHIVHan2 , except that the supernatants1996). The SHIVNM-3rn was constructed using the env,
vpu, rev, tat, vpr, and nef from NL432 and the originally from infected rhPBMC were collected at days 6 and 8
after infection.described SHIVNM-3 (Shibata et al., 1991) as starting mate-
rial (Kuwata et al., 1995). This parental virus SHIVNM-3 has The 2/95 stock of SHIVW6.1D (Ranjbar et al., 1997) was
passaged four times in vivo before preparing the finalbeen used successfully to infect cynomolgous monkeys
(Sakuragi et al., 1992). SHIVNM-3rn was selected for in vivo rhPBMC-derived stock. One milliliter of (10
5 TCID50) 2/
95 stock was inoculated intravenously (IV) into rhesustitration because (i) in a pilot study in rhesus macaques
it had induced a persistent low level of viremia for more monkeys (2455 and 3829). PBMC (351 106) from monkey
3829 obtained 2 weeks after infection were injected IVthan a year after infection (Stahl-Hennig, personal com-
munication) and (ii) it enables studies on the efficacy of into a second monkey (3070). PBMC (50 1 106) from
monkey 3070 obtained 2 weeks after infection were in-vaccines based on HIV-1 nef. The SHIVW6.1D was con-
structed (Ranjbar et al., 1997) by replacing an NheI/AvrII jected IV in a third monkey (L). Finally monkey 3806 re-
ceived 601 106 PBMC from monkey L, collected 2 weeksfragment encompassing gp120 and Dgp41 of the chime-
ric virus SHIV-4 (Li et al., 1992) with the equivalent region after infection. PBMC isolated 2 weeks after infection
from monkey 3806 were cocultured with C8166. Infectionof env and vpu from the clone 320.3, which was derived
from an HIV-1-infected patient (Groenink et al., 1991). and production of SHIVW6.1D were scored by observation
of syncytia formation/cytopathic effect (CPE) and p27 pro-
Preparation of the virus stocks duction. Infected C8166 cells were cultured for 4 weeks
with regular replenishment of medium and one additionSHIVsf13 was first propagated on C8166 T-cells in RPMI
1640 with 10% FCS. Cells were incubated with polybrene of fresh C8166 cells. Supernatant from these cocultures
were collected and stored at 0807 as a seed stock. To(5 mg/ml) for 1 hr at 377 followed by infection with the
SHIVsf13 virus. Supernatant was collected and stored at obtain a rhPBMC-derived SHIVW6.1D stock, the same pro-
cedure was used as described above for the SHIVsf130807 (seed stock). To obtain a rhPBMC-derived stock,
Concanavalin A (Con A, 10 mg/ml, 3 days) and IL-2 (100 stock, except that autologous noninfected PBMC (taken
from monkey 3806) were used.U/ml, 5 days) stimulated heterologous rhPBMCs were
incubated with polybrene (5 mg/ml) for 1 hr at 377, fol-
TCID50 determination of rhPBMC virus stockslowed by infection with the seed stock, and cultured for
10 days in a feeder system as previously described
The 50% tissue culture infectious doses (TCID50) of the(Heeney et al., 1994). The supernatant from this culture
rhPBMC-propagated SHIVsf13 , SHIVHan2 , and SHIVW6.1Drepresents a rhPBMC-derived SHIVsf13 stock; it was fil- were determined by infecting C8166 cells in 24 wells
tered (0.22 m), frozen in aliquots, and its p27 concentra-
plates (0.5 1 106 per well) with dilutions of the viruses
tion was determined using the SIV core antigen capture
starting from 1:10 followed by fivefold serial dilutions in
ELISA (Coulter, Hialeah, FL).
duplicate. The wells were scored for the presence of
SHIVHan2 virus stock was prepared as follows: M8166 syncytia after 3 weeks, and subsequently the TCID50cells (a subclone of C8166 cells) were transfected with
were calculated using the Ka¨rber formula. The TCID50 ofthe SHIVHan2 molecular clone and the supernatant ob- SHIVNM-3rn was determined similarly with serial 10-foldtained was used to infect fresh M8166 cells. Supernatant
dilutions of virus. Those cultures were assessed for vi-
from this infection was stored at 0807 (seed stock). For
rus-induced CPE over 14 days.
the generation of a rhPBMC-derived stock, PBMC from
six different rhesus monkeys were stimulated with Con MID50 determination of rhPBMC virus stockA (10 mg/ml) for 24 hr in 50% CG medium (Vitromex,
Vilshofen, Germany)/50% RPMI 1640 with 10% FCS. Cells The in vivo infectivities of the rhPBMC-derived SHIVsf13 ,
SHIVHan2 , SHIVNM-3rn , and SHIVW6.1D viruses were exam-from each monkey were pelleted and resuspended sepa-
rately in 1 ml of the seed stock followed by an adsorption ined in rhesus monkeys (Macaca mullata). Groups of
mature rhesus monkeys (male or female) were inocu-period of 1.5 hr at room temperature. Thereafter, cells
were replenished with medium supplemented with 20 lated IV with 1 ml of either undiluted or a 1001, 1002, 1003,
1004, or 1005 dilution of the various rhPBMC stocks. ToU IL-2 per milliliter. Twenty-four hours later cells were
washed three times to remove residual virus and kept in determine the MID50 upon IVAG inoculation, groups of
female monkeys were first synchronized with respect tomedium with IL-2 for 14 days. Supernatants were tested
for p27 antigen three times a week and were collected their hormonal cycle by inducing menses by three IM
injections of 0.02 mg/kg of oestradiol benzoate (Intervet,when their p27 concentrations were highest, usually at
days 13 and 15 after infection. After checking the super- Angers, France) at 48-hr intervals (Dr. R. Le Grand, per-
sonal communication). The female monkeys were inocu-natant from each individual rhPBMC culture for its p27
content, supernatants were pooled, divided in aliquots, lated 4 weeks after start of hormone treatment with 1 ml
of either undiluted or 1001, 1002, or 1003 dilution ofand stored in liquid nitrogen.
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SHIVsf13 stock as described (Miller et al., 1994). Blood clone MT310), -CD8 (cytotoxic cells, IgG1k, clone DK25),
-CD3 (T cells, clone FN18), -CD29 (memory cells, IgG2ak,samples were taken from weeks 1 to 13 postinoculation
and analyzed for plasma antigenemia, the presence of clone K20) (DAKO, Glostrup, Denmark), -CD69 (early acti-
vation marker, IgG1, clone L78) (Becton–Dickinson (BD),proviral DNA, levels of cell-associated viremia, and anti-
HIV-1 env antibodies. Aalst, Belgium). FACS analysis of PBMC was performed
as follows: 50 ml of heparinized whole blood was incu-
Viral load of inoculated rhesus monkeys bated at room temperature for 20 min with 5 ml mAbs
coupled directly to phycoerythrin (PE) or fluorescein-iso-At various time points plasma and PBMC were iso-
lated. Antigenemia was measured in plasma using a thiocyanate (FITC) specific for surface antigens or with
a mixture of mAbs for double labeling. Erythrocytes werehighly sensitive commercial HIV-1 p24 capture ELISA (In-
nogenetics, Belgium) with a known standard (the sensi- lysed with 1.0 ml FACs lysing solution (BD) at room tem-
perature for 10 min and the cells were then pelleted bytivity of this assay was higher than the sensitivity of the
SIV core antigen capture ELISA from Coulter). PBMC centrifugation. PBMC were fixed overnight with 1–2%
formalin in PBS and analyzed in a FACsort flow cytometerwere purified from heparinized whole blood by lympho-
cyte separation medium (LSM, Organon Technica, Dur- using Cell Quest software (BD).
ham). For determination of cell-associated viral load
(quantitative virus isolation: QVI), fivefold serial dilutions RESULTS
of isolated PBMC were cocultivated with 0.51 106 C8166
In vitrocells per well in duplicate in 24-well plates for 3 weeks.
After 3 weeks the cultures were scored for the presence The rhPBMC-derived SHIVsf13 stock contained 94
of syncytia to determine the endpoints from which the ng/ml of p27 and had a TCID50/ml of 7.1 1 104 on
number of infected PBMC were calculated. The cell-as- C8166. The in vitro infectivity of the SHIVHan2 rhPBMC-
sociated viral load in SHIVNM-3rn-infected rhesus monkeys derived stock (264 ng/ml of p27) on C8166 cells was
was determined as described (Stahl-Hennig et al., 1996). 1.0 1 104 TCID50/ml. The infectivity of the SHIVNM-3rn
stock (210 ng/ml of p27) was 6.3 1 104 TCID50/ml andDetection of proviral DNA in peripheral blood
the SHIVW6.1D stock (88 ng/ml of p27 antigen) was 1.2mononuclear cells 1 103 TCID50/ml.
For determining proviral DNA in PBMC, PCR was per-
formed as described previously using env-derived prim- In vivo
ers (Bogers et al., 1995). Detection limit was 6 genome
Determination of the MID50 was performed in rhesusequivalents per 106 PBMC.
macaques either upon IV (SHIVsf13 , SHIVHan2 , SHIVNM-3rn ,To amplify gag-specific sequences of SIV from the
and SHIVW6.1D) or upon IVAG inoculation (SHIVsf13).PBMC of SHIVNM-3rn-infected monkeys a nested PCR pro-
cedure was employed as reported previously (Petry et SHIVsf13al., 1995).
All animals receiving IV undiluted, 1001, 1002, or 1003
Detection of HIV-1 gp120 specific antibody titres of the SHIVsf13 stock became PCR and/or virus isolation
(VI) positive 2–4 weeks postinfection (Table 1). In con-Anti-HIV-1 env antibodies in plasma from infected
animals were measured using antigen-specific ELISAs. trast, animals infected with the 1004 dilution remained
PCR and VI negative at all timepoints. Plasma antigen-To determine anti-SF13, anti-NM-3rn, and anti-W6.1D
titers, the following antigens were used: SF2 gp120, emia varied from 2600 pg/ml to undetectable levels. Cell-
associated virus load was low: one monkey infected IVIIIB gp120, and W6.1D gp120 (MRC), respectively. Mi-
crotiter plates (96 wells, Titertex, ICN, The Netherlands) with undiluted SHIVsf13 virus contained 125 infected cells
per 106 PBMC 2 weeks after infection (Table 1). Monkeyswere coated with 1 mg/ml of the antigen overnight at
47. The wells were blocked with PBS/0.1% Tween 20/ infected with diluted virus stock contained 5–25 virus
producing cells per 106 PBMC at week 2. In all animals1% bovine serum albumin for 1 hr at 377. Plasma dilu-
tions were incubated for 1.5 hr at 377 followed by sheep the numbers of infected cells gradually declined to less
than 1 virus producing cell per 106 PBMC at week 8anti-human Ig-biotin antibodies (Amersham, The Neth-
erlands) for 1.5 hr at 377. Streptavidin – horse radish postinfection. The MID50 of the SHIVsf13 challenge stock
was calculated to be 3.2 1 103 after IV inoculation. Eightperoxidase conjugate (Amersham) was incubated for
0.5 hr followed by OPD substrate (Sigma). Optical Den- of fourteen infected animals were tested for the presence
of anti HIV-1 env-specific antibodies which cross-reactsity was measured at 490 nm.
with SF2 gp120 antigen by week 2 postinfection. After
Flowcytometric analysis IVAG inoculation only animals receiving the undiluted
SHIVsf13 stock and one animal receiving a dilution of 1/The mouse mAbs specific for human surface antigens
used in this study included: anti CD4 (T helper, IgG1k, 100 became infected at weeks 2 and 4 (Table 1) and
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TABLE 1
IV and IVAG Titration of rhPBMC-Derived SHIVsf13 in M. mulatta
IV titration of SHIVsf13 in rhesus macaques
DNA-PCR QVI Plasma p27 Anti-HIV-1 gp120 titers
Virus (wpi) (wpi) (wpi) (wpi)
stock
dilution Monkey 2 4 6 8 1 2 4 6 8 2 4 2 4 6 8
Undil. 3952 / / nd nd 5* 5 1 /** 1 236*** nd 100 400 800 800
NU / / nd nd 1 125 5 / 1 134 nd 50 100 100 100
10-1 TO / / nd nd nd / / / nd 400 nd nd nd nd nd
TS / / nd nd 1 25 5 / 1 670 nd 100 200 400 400
3887 / / nd nd nd / / / nd 2600 nd nd nd nd nd
2P / / nd nd 1 25 5 / 1 234 nd 100 100 400 1600
10-2 VJ / / nd nd 1 5 1 / 1 333 nd 100 100 200 200
1AQ / / nd nd 1 5 5 / 1 50 nd 50 50 50 50
K94 / / nd nd nd / / / nd 186 nd nd nd nd nd
OW / / nd nd nd / / / nd 184 nd nd nd nd nd
10-3 IDM / 0 nd / 1 1 1 / 1 nd 50 nd 100 100 100
XQ / / nd / 1 5 5 / 1 nd 50 50 100 50 100
NL / / nd / nd / / 0 0 nd 50 nd nd nd nd
YU 0 / nd / nd 0 / / / nd 50 nd nd nd nd
10-4 1DW 0 0 nd 0 nd 0 0 0 0
1AJ 0 0 nd 0 nd 0 0 0 0
OI 0 0 nd 0 nd 0 0 0 0
1H 0 0 nd 0 nd 0 0 0 0
IVAG titration of SHIVsf13 in rhesus macaques
DNA-PCR QVI Plasma p27 Anti-HIV-1 gp120 titers
Virus (wpi) (wpi) (wpi) (wpi)
stock
dilution Monkey 1 2 4 6 8 13 1 2 4 6 8 13 4 6 2 4 6 8 13
Undil. AG 0 / / / / / 1 12* 50 25 1 1 50** nd 50 50 100 200 200
2378 0 0 / / / / 1 1 8 16 16 1 nd 507 50 50 50 50 50
3036 0 0 / / / / 1 1 24 32 1 1 nd 50 50 50 50 50 100
1001 3822 0 0 0 0 0 0 1 1 1 1 1 1
BB105 0 0 0 0 0 0 1 1 1 1 1 1
1002 3176 0 0 0 0 0 0 1 1 1 1 1 1
3674 0 0 / / / / 1 1 50 4 8 1 nd nd nd 50 50 50 800
1003 3985 0 0 0 0 0 0 1 1 1 1 1 1
BU 0 0 0 0 0 0 1 1 1 1 1 1
Note. Groups of monkeys were inoculated IV or IVAG with undiluted, 1001, 1002, 1003, or 1004 diluted rhPBMC-derived SHIVsf13 stock. Blood
sampling was performed at weeks 1, 2, 4, 6, 8, and 13 postinfection. wpi, week post infection; QVI, quantitative virus isolation; nd, not done; *,
number of infected cells per 106 PBMC; **, / in QVI column means positive for virus isolation but not quantitated. ***, pg/ml. Anti-HIV-1 gp120
titers represent the highest plasma dilutions that gave twice the background values.
virus load peaked at weeks 4 to 6. From these results SHIVNM-3rn
the MID50 of SHIVsf13 for IVAG inoculation was calculated
Macaques inoculated with SHIVNM-3rn became in-to be 10.
fected at dilutions up to 1004 of the virus stock (Table
SHIVHan2 3) and this stock was calculated to have a MID50 of 3.2
1 104. The viral load was higher than that observed forMonkeys inoculated IV with the SHIVHan-2 stock virus
SHIVsf13 and SHIVHan2 infection (up to 2048 per 10
6became infected at dilutions up to 1004 (Table 2), and
PBMC) and persisted at low levels beyond the observa-showed relatively low plasma antigenemia levels. The
tion period (data not shown). Some animals infectedMID50 was calculated to be 3.21 104. The cell associated
with SHIVNM-3rn had measurable plasma antigenemiaviremia which peaked at 2 to 4 weeks postinoculum was
levels and all infected animals developed anti HIV-1relatively low and of short duration (8 weeks). All infected
animals developed anti-gp120 antibodies. gp120 antibodies.
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TABLE 2
IV Titration of rhPBMC-Derived SHIVHan-2 in M. mulatta
DNA-PCR QVI Plasma p27 Anti-HIV-1 gp120 titers
Virus (wpi) (wpi) (wpi) (wpi)
stock
dilution Monkey 2 4 6 8 1 2 4 6 8 12 2 4 2 4 6 8 12
1002 HT36 / / nd nd 2* 16 2 2 2 nd 50** nd 200 800 800 800 nd
1003 2U / / nd nd  64 8 1 2 nd 50 nd 800 800 800 400 nd
1004 1DW 0 / / 0 nd 1 8 1 1 1 nd 50 100 200 400 800 6400
1AJ 0 / / 0 nd 1 128 32 2 1 nd 145 800 3200 3200 1600 3200
1005 OI 0 0 0 0 nd 1 1 1 1 nd
1H 0 0 0 0 nd  1 1 1 nd
Note. Groups of monkeys were inoculated IV with 1002, 1003, 1004, and 1005 diluted rhPBMC-derived SHIVHan2 stock. Blood sampling was performed
at weeks 1, 2, 4, 6, 8, and 12 weeks postinfection. wpi, week postinfection; QVI, quantitative virus isolation; nd, not done; *, number of infected cells
per 106 PBMC; **, pg/ml. Anti-HIV-1 gp 120 titers represent the highest plasma dilutions that gave twice the background values.
SHIVW6.1D in a longer or higher viral replication in the blood of the
recipient macaque.
Monkeys that received IV rhPBMC-derived SHIVW6.1D FACS analysis revealed that there were no significant
at dilutions of 1001, 1002, or 1003 were DNA PCR and
changes in peripheral T-cells over time in any of the
QVI positive at week 2 postinoculation (Table 4). Plasma
infected monkeys (data not shown); no significant de-
antigen levels were detected at week 2 and did not show
crease of CD4/ cell numbers was observed in any ani-
a linear relation with the virus inoculum dose. Animals
mal during this study, and CD4/CD8 ratios remained rela-
injected with a dilution of 1004 of the virus stock remained
tively constant over time (fluctuations within normal
PCR as well as QVI negative. The highest virus load
ranges). None of the macaques infected directly, or
(16–128 per 106 PBMC) was observed at week 2 or 4
through passage with the various env SHIV virus strains,
postinfection and declined gradually thereafter. All in-
have shown clinical evidence of progression to disease
fected animal developed anti-W6.1D gp120-specific anti-
up to 13 months postinfection.
bodies.
In an attempt to increase the virulence of SHIVW6.1D , DISCUSSION
sequential rapid passage of the 2/95 stock was per-
formed in vivo (Table 5). The cell-associated viral load Chimeric SIVmac viruses expressing HIV-1 envelope
proteins may facilitate the preclinical evaluation and de-obtained at 2 weeks postinoculation in the second pas-
sage macaque (3070) was indeed 10-fold higher than velopment of candidate HIV-1 vaccines. Today macaques
have been infected with several chimeric viruses ex-that of the two macaques inoculated with the 2/95 stock
of virus. However, the transfer of PBMC harvested at this pressing either the HIV-1 env or RT genes. Recently, a
broader range of chimeric SHIVs, expressing envelopestime point from 3070 to a third macaque (L) did not result
TABLE 3
IV Titration of rhPBMC-Derived SHIVNM-3rn in M. mulatta
DNA-PCR QVI Plasma p27 Anti-HIV-1 gp120 titers
Virus (wpi) (wpi) (wpi) (wpi)
stock
dilution Monkey 2 4 8 2 4 6 8 12 2 4 6 4 8 12
1001 1841 / / nd 256* nd nd 16 16 50** 50 50 100 3200 3200
1002 1875 / / nd 256 64 nd 8 2 65 50 50 100 3200 3200
1.6 1 1003 1871 / / nd 512 2048 64 1 1 270 370 50 400 1600 6400
1885 / / nd 64 1024 256 16 4 50 50 1230 100 800 3200
1003 8004 / / / 0 16 512 32 1 50 50 50 100 100 3200
1004 8144 / / / 32 128 4 1 0.33 50 50 70 100 400 6400
8150 / / / 0 128 16 16 4 50 50 50 100 100 3200
1005 1914 0 0 0 0 0 0 0 0 nd nd nd 100 100 100
Note. Groups of monkeys were inoculated IV with 1001, 1002, 1.6 1 1003, 1003, 1004, and 1005 diluted rhPBMC-derived SHIVNM-3rn stock. Legend
as for Table 2.
AID VY 8744 / 6a46$$$141 08-13-97 20:31:42 vira AP: VY
115IN VITRO AND IN VIVO INFECTIVITY OF SHIV
TABLE 4
IV Titration of rhPBMC-Derived SHIVW6.1D in M. mulatta
QVI Plasma p27 Anti-HIV-1 gp120 titers
Virus (wpi) (wpi) (wpi)
stock
dilution Monkey 2 4 6 8 12 2 2 4 6 8 12
1001 FS 128* 24 24 2 4 2500** 100 600 6400 6400 6400
10A 128 128 16 1 4 1640 50 50 400 400 400
1002 2503 8 24 6 nd 1 190 50 50 50 1600 6400
2523 16 8 8 1 1 50 50 50 200 200 200
1003 2715 32 16 1 1 1 1345 50 100 50 3200 3200
2733 32 64 16 24 1 2500 50 100 3200 6400 6400
1004 2815 1 1 1 1 1
3339 1 1 1 1 1
Note. Groups of monkeys were inoculated with 1001, 1002, 1003, and 1004 diluted rhPBMC-derived SHIVW6.1D stock. Legend as for Table 2.
from different HIV-1 isolates, have become available. In predict the in vivo replication capacity: the ratio TCID50/
MID50 varied between 0.3 and 20 for the four SHIV strains.this study we compared rhPBMC-propagated SHIVsf13 ,
SHIVHan2 , SHIVNM-3rn , and SHIVW6.1D virus stocks for their This emphasizes the importance of determining the
MID50 for each virus preparation and the risks of extrapo-virulence in vitro and in vivo. All monkeys infected IV with
these viruses developed a cell-associated peak viremia lating to in vivo infectivity or virulence from in vitro data.
Recently it has been shown that SHIV virus strains can2–4 weeks after infection and infectious virus was recov-
erable at almost all time points. Plasma antigenemia lev- cross both the rectal mucosal barrier (Trivedi et al., 1994)
and the vaginal mucosal barrier (Lu et al., 1996a). In theels, when detectable, did not show a clear relationship
with the virus dose administered. The duration of viremia present study we set out to determine if SHIVsf13 was
able to infect via the vaginal mucosa. The inoculum dosewas generally short, and the number of infected PBMCs
declined to low levels (in case of SHIVNM-3rn) or to unde- required for successful infection was approximately 300
times higher than that needed for IV infection. The lowtectable levels within 2 to 3 months. All SHIV-infected
animals developed anti HIV-1 env-specific antibodies, IVAG infectivity with SHIVsf13 might be due to the fact
that we used only a single inoculation, in contrast to themost had seroconverted by 2 weeks after infection. Our
results failed to demonstrate a linear relationship be- multiple inoculations reported elsewere (Lu et al., 1996a).
Mucosal infectivity might also be influenced by proges-tween the dose of inoculum virus and the viral load in
PBMC; this was true for SHIVHan2 , SHIVNM-3rn , and terone levels at the time of SHIV inoculation; low levels
rendered macaques less susceptible to SIV/SHIV infec-SHIVW6.1D . Animals inoculated with low doses of virus
were sometimes found to have a higher number of virus tion (Marx et al., 1996). As the ability to cross mucosal
barriers depends on specific env sequences (Lu et al.,producing PBMC than those infected with undiluted virus
stock. Also, the virus dose did not influence the duration 1996a), HIV-1 env-based SHIVs yield important insights
into mucosal infections as certain env sequences facili-of viremia. Finally, the in vitro infectivity (TCID50) did not
TABLE 5




number Monkey 1 2 4 6 8 10 12 2
1 2455 nd 5* 16 2 1 1 1 90**
3829 nd 50 8 2 2 2 1 1110
2 3070 32 520 60 16 1 1 1 2500
3 L 64 32 2 1 1 1 1 270
4 3806 1 250 2 1 1 1 1 50
Note. SHIVW6.1D stock obtained from C8166 cells was serially passaged in vivo as described under Materials and Methods. Blood sampling was
performed at weeks 1, 2, 4, 6, 8, 10, and 12. wpi, week postinfection; QVI, quantitative virus isolation; nd, not done; *, number of infected cells per
106 PBMC. **, pg/ml.
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